PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Addiction. Author manuscript; available in PMC 2011 January 1.
Published in final edited form as:
PMCID: PMC2808705
NIHMSID: NIHMS148070

Cognitive Enhancement as a Pharmacotherapy Target for Stimulant Addiction

Abstract

Background

No medications have been proven to be effective for cocaine and methamphetamine addiction. Attenuation of drug reward has been the main strategy for medications development, but this approach has not led to effective treatments. Thus, there is a need to identify novel treatment targets in addition to the brain reward system.

Aim

To propose a novel treatment strategy for stimulant addiction that will focus on medications enhancing cognitive function and attenuating drug reward.

Methods

Preclinical and clinical literature on potential use of cognitive enhancers for stimulant addiction pharmacotherapy was reviewed.

Results and conclusions

Cocaine and methamphetamine users show significant cognitive impairments, especially in attention, working memory and response inhibition functions. The cognitive impairments seem to be predictive of poor treatment retention and outcome. Medications targeting acetylcholine (Ach) and norepinephrine (NE) are particularly well-suited for enhancing cognitive function in stimulant users. Many cholinergic and noradrenergic medications are on the market, have a good safety profile, and low abuse potential. These include galantamine, donepezil, and rivastigmine (cholinesterase inhibitors), varenicline (partial nicotine agonist), guanfacine (alpha2-adrenergic agonist), and atomoxetine (norepinephrine transporter inhibitor). Future clinical studies optimally designed to measure cognitive function as well as drug use behavior would be needed to test the efficacy of these cognitive enhancers for stimulant addiction.

Keywords: Cognition, stimulants, cognitive enhancers, pharmacotherapy

INTRODUCTION

Stimulant addiction, most notably cocaine and methamphetamine, continues to be an important public health problem, with an estimated 36 million current users worldwide (1). Unfortunately, no medications have been proven to be effective for cocaine and methamphetamine addiction in spite of the large number of compounds screened in randomized clinical trials (25). For stimulant addiction, the traditional medications development strategy has been to identify medications that attenuate drug reward (5), which is mediated by the dopaminergic pathway from the ventral tegmental area (VTA) to the nucleus accumbens (subcortical structures in the brain). This strategy, however, has not resulted in effective medication development. Thus, there is a clear need to critically examine our medication development strategies and identify new treatment targets for stimulant addiction.

A new strategy proposed in this review is to develop new science-based treatment targets that will broaden our screening methods for potential medications for addictions. Converging evidence, especially from human neuroimaging and cognitive neuroscience studies, indicates that cognitive functions, particularly inhibitory cognitive control, are closely linked to addictive behaviors (69). These cognitive functions, which are attributed to the prefrontal cortex (PFC), can also be improved by selective medications known as cognitive enhancers. In this review, I will first overview cognitive function in stimulant addiction and follow with examples of cognitive enhancers that may be used for the treatment of stimulant addicted individuals. An ideal cognitive enhancer for addiction pharmacotherapy should enhance cognitive function and attenuate drug reward. Although such medications remain to be identified, promising candidates for addiction pharmacotherapy will be reviewed and future research directions will be discussed. This will be a selective review of potential use of cognitive enhancers for stimulant addiction with a focus on medications development. Systematic reviews of medications under investigation for stimulant addiction can be found elsewhere (2-5). For a broader perspective of cognitive remediation in stimulant addiction, the reader is referred to an excellent review by Vocci (9).

COGNITIVE FUNCTION AND ADDICTION

Many studies have demonstrated that chronic use of cocaine and methamphetamine is associated with deficits in cognitive functioning, including decision-making, response inhibition, planning, working memory, and attention (1015). In a recent meta-analysis (12), cocaine users (n=481) showed greater impairment in attention, visual memory, design reproduction, and working memory compared to healthy controls (n=586). These deficits seem to be correlated with the severity of cocaine use, suggesting a dose-related effect of drug use (13). Similarly, methamphetamine dependent individuals showed deficits in memory, attention, set shifting, response inhibition, and decision-making abilities (14, 1620). The severity of impairments in verbal memory and psychomotor function for methamphetamine users were correlated with loss of dopamine transporters in the striatum and nucleus accumbens (21, 22). The neural substrates of these deficits have been examined in functional imaging studies. A recent PET study demonstrated low glucose metabolism in the anterior cingulate and high glucose metabolism in the lateral orbitofrontal area, middle and posterior cingulate, amygdala, ventral striatum, and cerebellum of recently abstinent methamphetamine abusers (23). These and many other studies point to a dysfunction in the prefrontal cortex (PFC) in stimulant users (24). The PFC serves many functions that are highly relevant for addiction, including attention, working memory, response inhibition, and decision-making (8, 25).

Among PFC functions, disruptions in inhibitory control of the PFC have been the centerpiece in many theories of addiction (68). The inhibitory function of the PFC is especially important when the individual needs to override a reflexive prepotent response, such as drug-taking behavior in response to drug cues. In fact, compulsive drug use, the hallmark of drug addiction; is characterized by behavioral inflexibility and more specifically a decreased ability to inhibit responses to drug related cues, also commonly called impulsivity (26).

From a treatment perspective, the inhibitory control function of the PFC has two unique features. First, inhibitory control and other cognitive functions of the PFC are greatly influenced by the neurochemical environment of the PFC to a greater degree than other brain regions (27). This quality makes PFC functions very susceptible to genetic and environmental influences including stress. However, this sensitivity also makes PFC cognitive functions amenable to treatment with selective cognitive enhancers. Second, inhibitory control is not a circumscribed function of the PFC. Rather, many PFC areas contribute to inhibitory function including the orbitofrontal cortex, anterior cingulate cortex, dorsolateral PFC, dorsomedial PFC, and inferior frontal gyrus (28, 29). Moreover, inhibitory control is closely linked to other PFC functions, most notably to attention and working memory. For example, lapses in attention during early abstinence have been linked to relapse, possibly by reducing behavioral inhibition (30). Similarly, working memory function is essential for optimum inhibitory control. Under high working demand, cocaine users have reduced inhibitory control measured by impaired suppression of prepotent responses compared to healthy controls (31). As these examples suggest, optimum inhibitory control function depends on other PFC functions including attention and working memory. One possible, yet untested, treatment implication of these findings is that in stimulant users, medications improving attention and working memory may lead to better inhibitory control.

COGNITIVE DEFICITS AND TREATMENT OUTCOME

Despite evidence supporting the presence of cognitive deficits in drug users including decision-making, response inhibition, planning, working memory, and attention, the clinical implications of these findings have received limited attention, perhaps due to the subtle nature of these deficits and observations that at least some may be reversible following cessation of drug use. However, former amphetamine users have shown cognitive impairments similar to current users, suggesting that these cognitive impairments were not reversible after short-term abstinence (32). Similarly in a longitudinal study of methamphetamine-dependent individuals participating in an outpatient treatment program (33), the group continuing to use methamphetamine performed best in cognitive tests, followed by the recent relapse group, and the abstinent group (6 months) performed the poorest overall. In addition, recent cocaine use seems to mask underlying cognitive deficits in cocaine users (34), further indicating a possible decrease in cognitive functioning during early abstinence from stimulant use.

Several lines of evidence link cognitive function to treatment outcome in stimulant users. In a series of studies, Aharonovich and colleagues have demonstrated that cognitive impairment renders cocaine users less able to benefit from behavioral treatment (35, 36). That is, cocaine users who dropped out of treatment had significantly lower performance on attention, memory, spatial ability, speed, accuracy, global functioning, and cognitive proficiency tests. Similarly, in a study with treatment-seeking cocaine users, performance in the Stroop color-word interference task, a reliable measure of inhibitory control function, at treatment entry was predictive of treatment retention (37). Further, impulsivity or poor response inhibition as a personality trait, measured with the Barratt Impulsiveness Scale (BIS-11), was a predictor of poor treatment retention in cocaine users (38, 39). In previous studies with users of other substances, deficits in cognitive functioning and inhibitory control also predicted higher drop-out rates and poor treatment response (4042). These findings emphasize the importance of addressing cognitive functioning in drug users early in treatment to alleviate cognitive deficits that may impact treatment adherence and outcome.

MEDICATIONS TARGETING COGNITIVE FUNCTION AND ADDICTION

Cognitive functioning in the PFC is modulated by many neurotransmitters, including glutamate, GABA, serotonin, acetylcholine (ACh), dopamine (DA), and norepinephrine (NE) (43). Medications enhancing dopaminergic transmission, including methylphenidate and amphetamine derivatives, are most commonly used, especially for the treatment of attention deficit hyperactivity disorder (ADHD). These dopaminergic enhancers have also shown promise in short-term clinical trials for the treatment of cocaine and amphetamine addiction (4446). However, these medications have significant abuse potential, and the safety and feasibility of their long-term use in addicted populations remains to be determined (47). Another cognitive enhancer is modafinil, which has mixed neurotransmitter actions, including GABA, glutamate, and dopaminergic transmitters. Modafinil has been evaluated for cocaine and methamphetamine addiction with some promising findings (48). However, modafinil may also have abuse potential, which may limit its utility in stimulant addicted individuals (49).

As will be summarized below, based on our recent review of the literature (50, 51), medications targeting ACh and NE share several features that make them potential treatments to improve inhibitory control function in stimulant addicted individuals. First, both ACh and NE have well established effects on PFC cognitive functions that are impaired in drug users, including response inhibition, attention, and working memory. Second, both ACh and NE are emerging treatment targets for addiction pharmacotherapies. Third, several cholinergic and noradrenergic medications are on the market, have a good safety profile, and have low abuse potential.

Cholinergic System

Acetylcholine participates in many CNS functions, including sensory and motor processing, sleep, nociception, mood, stress response, attention, arousal, memory, motivation, and reward (5254). These diverse functions are mediated by nicotinic and muscarinic cholinergic receptors. Cholinergic neurons are either projection neurons, terminating diffusely in the brain (including in the PFC), or interneurons, which are located mainly in the striatum and nucleus accumbens (55). While cholinergic projection neurons are critical in cognitive function, cholinergic interneurons integrate cortical and subcortical information related to reward (56, 57).

Cognition

ACh plays an important role in mediating PFC cognitive functions, including attention and declarative and working memory, which are possibly mediated through nicotinic cholinergic receptors (54, 58). Recent studies also suggest that reduction in ACh release in the PFC may be critical in mediating attentional deficits associated with chronic amphetamine exposure in rats (26, 59, 60). The reduction in ACh release in response to cognitive tasks (called ACh “freezing”) may be alleviated by medications increasing ACh release like cholinesterase inhibitors.

Reward

ACh also interacts with the dopaminergic reward system, especially in the nucleus accumbens. Lesioning of these neurons by a cholinergic immune toxin results in greater sensitivity and preference to cocaine in mice (61). In contrast, enhancement of cholinergic transmission by treatment with the cholinesterase inhibitor physostigmine decreased cocaine self-administration in monkeys (62). Similarly, donepezil reduced locomotor sensitivity and preference to cocaine in mice (63).

Cholinergic Medications

Two classes of medications targeting the cholinergic system may potentially be useful for stimulant addiction: cholinesterase inhibitors and partial nicotine agonists.

Cholinesterase inhibitors

Cholinesterase inhibitors increase the synaptic concentrations of ACh, which results in increased stimulation of both nicotinic and muscarinic ACh receptors. A number of cholinesterase inhibitors, including tacrine, rivastigmine, donepezil, and galantamine are available for clinical use for the treatment of dementia (6466). Cholinesterase inhibitors have also been evaluated for other disorders characterized by cognitive impairment, including Parkinson’s disease, traumatic brain injury, and schizophrenia (6769). The pharmacological and side effect profiles of cholinesterase inhibitors differ. Tacrine has limited use due to hepatotoxicity and short half-life (6769). Galantamine also binds to nicotinic receptors, especially α7 and α4β2 subtypes, and enhances responses to acetylcholine (70). Donepezil and rivastigmine are more potent cholinesterase inhibitors compared to galantamine (71).

There have been few human studies examining cholinesterase inhibitors as potential treatments for amphetamine addiction. Janowsky et al.(72) reported that physostigmine cholinesterase inhibitors attenuate the subjective effects of methylphenidate, a stimulant medication, in bipolar and schizophrenic patients. Recently, De La Garza et al. examined the effects of a cholinesterase inhibitor, rivastigmine (1.5 or 3 mg/day), on intravenous methamphetamine responses (30 mg/day) in 23 methamphetamine-dependent humans (73). In that study, 3 mg rivastigmine attenuated some of methamphetamine’s subjective effects, including “desire” and “anxiety.” These findings are promising and warrant further studies evaluating cholinesterase inhibitors as potential treatments for stimulant addiction.

In a clinical trial, 10 mg/day donepezil, a cholinesterase inhibitor, was well tolerated but did not reduce cocaine use behavior (74). The sample size of the study was small (only 17 subjects assigned to donepezil), providing inadequate statistical power to test the study hypothesis. Further, only one dose of donepezil was evaluated. In spite of these limitations, those treated with donepezil did show significant reductions in craving and other indexes of addiction severity to cocaine and other drugs.

In a recent study (75), our group examined the cognitive effect of galantamine treatment in 28 abstinent cocaine users. Preliminary analysis indicates that galantamine administered at 8 mg/day for 10 days improved sustained attention better than placebo, measured the Rapid Visual Information Processing (RVIP) subtest of the CANTAB. Most notably, galantamine treatment, compared to placebo, was associated with shorter mean latency score for the RVIP task. These results indicate the feasibility, safety, and promise of galantamine as a cognitive enhancer among cocaine users.

Partial nicotine agonists

Varenicline, a partial agonist of α4β2 nicotinic receptors, has recently been marketed for smoking cessation. Several other partial nicotinic agonists, including dianicline and ispronicline, are undergoing human studies for smoking cessation and treatment of dementia (76). In preclinical studies, varenicline has been shown to alleviate learning deficits in mice induced by alcohol administration (77) or nicotine withdrawal (78). In a recent study of cigarette smokers, 10 days of varenicline treatment improved working memory and attention deficits induced by nicotine withdrawal (79). Another similarly acting partial nicotine agonist, AZD3480, enhanced attention and episodic memory functions in healthy volunteers (76).

Partial nicotinic agonists may also have value for stimulant addiction pharmacotherapy, given the role of nicotinic receptors in stimulant effects. For example, nicotine treatment reduced methamphetamine-seeking behavior in rodents (80). In humans, nicotine may change typical subjective and physiological responses to stimulants. In one study, a 14 mg nicotine patch attenuated cocaine-induced “high” and “stimulation” and increased the latency of detection of cocaine effects compared to placebo, without affecting physiological responses or the pharmacokinetics of cocaine (81). Rapid desensitization to nicotine’s effects has limited the use of nicotinic agonists. Varenicline and other partial nicotine agonists do not seem to cause rapid desensitization in nicotinic receptors (82) and may be useful to examine the contribution of nicotinic receptors in stimulant responses. Varenicline and other partial nicotinic agonists remain to be evaluated for stimulant addiction.

Noradrenergic System

The noradrenergic system uses norepinephrine (NE) as its main chemical messenger and serves multiple brain functions, including arousal, attention, mood, learning, memory, and stress response (83, 84). Noradrenergic neurons are localized in brainstem nuclei such as the locus ceruleus, and noradrenergic axons project diffusely to almost every part of the brain (85). NE’s effects are mediated by three families of adrenergic receptors: α1, α2, and β (86).

Cognition

Increasing evidence from preclinical and clinical studies indicate that NE is critical in many PFC cognitive functions, including sustained attention, working memory, and response inhibition (87, 88). The beneficial effect of NE on PFC cognitive functioning is thought to be mediated by the stimulation of postsynaptic alpha2-adrenergic receptors in the PFC (89). Alpha2-adrenergic receptors are targeted by several medications, including alpha2-adrenergic agonists (clonidine, lofexidine, and guanfacine) and norepinephrine transporter inhibitors (reboxetine and atomoxetine).

Reward

NE is also closely connected to the dopaminergic reward system. For example, lesioning of noradrenergic neurons in the locus ceruleus decreases DA release in the nucleus accumbens (90), and conversely, activation of locus ceruleus noradrenergic neurons increases the activity of dopaminergic neurons in the VTA (91). This regulation is mediated by the α1-adrenergic receptor subtype (92).

Noradrenergic Medications

Two classes of medications targeting NE may potentially be useful for stimulant addiction: norepinephrine transporter inhibitors and alpha2-adrenergic agonists.

Norepinephrine Transporter Inhibitor

Recently, two highly selective norepinephrine transporter (NET) inhibitors were developed for clinical use: reboxetine and atomoxetine. Some tricyclic antidepressants, including desipramine, also have NET inhibitor effects. However, these medications also interact with adrenergic and non-adrenergic receptors, making the precise role of NET inhibition difficult to elucidate (93). Reboxetine, an antidepressant medication, was evaluated in a 12-week open label study in 26 cocaine users. In that study, reboxetine was well-tolerated and reduced cocaine use suggesting its potential efficacy (94). However, reboxetine was not approved by the Food and Drug Administration FDA) for marketing in the US.

Atomoxetine, a medication used for the treatment of ADHD, is a selective norepinephrine transporter (NET) inhibitor that increases synaptic NE levels in the PFC (95, 96) and may increase cognitive functioning by stimulating postsynaptic alpha2-adrenergic receptors. Atomoxetine also increases dopamine levels in the PFC, but not in the striatum nor in the nucleus accumbens (95, 96). This discrepancy was attributed to sparse distribution of dopamine transporters in prefrontal cortex, indicating that NET significantly contributes to clearing of extracellular dopamine in this region (97). In contrast, amphetamines increase both DA and NE levels in the nucleus accumbens and in the PFC (98). These differential neurochemical effects likely contribute to the high and low abuse liability of amphetamines and atomoxetine, respectively (99, 100).

In preclinical studies, atomoxetine improved performance in various forms of impulsivity (101) and attention in rats (102) as well as reversal learning in rats and monkeys (103). Atomoxetine also improved attentional set-shifting deficits associated with prefrontal cortex (PFC) deafferentation in rats (104). In humans, atomoxetine improved response inhibition, measured with the Stop Signal test in healthy controls and patients with attention deficit hyperactivity disorder (105). In ADHD patients, atomoxetine also improved Stroop performance (106). As both methamphetamine and cocaine users have been reported to have slower Stop Signal Reaction times than controls (107, 108), it would be of interest to examine atomoxetine’s ability to improve performance on this task in stimulant users.

Recently, atomoxetine’s effects on the acute physiological and subjective responses to dextroamphetamine were examined in healthy volunteers (109). Four days of atomoxetine (40 mg/day, orally) treatment attenuated some of the subjective effects of dextroamphetamine, including ratings of “stimulated,” “high,” and “good drug effects.” Since the rating of “good drug effects” and “high” are predictive of reinforcing effects from amphetamines (110), their attenuation by atomoxetine supports its potential use as a treatment for stimulant addiction. Atomoxetine remains to be evaluated in clinical trials for stimulant addiction.

Alpha2-adrenergic Agonists

Guanfacine is an alpha2-adrenergic agonist similar to clonidine and lofexidine. Guanfacine is used for the treatment of hypertension, attention deficit hyperactivity disorder (ADHD), and opioid withdrawal. Guanfacine decreases noradrenergic activity by stimulating presynaptic alpha2-adrenergic receptors. Compared to clonidine, guanfacine is less sedating and has more selectivity for the alpha2 adrenergic receptors found in the prefrontal cortex, alpha2A subtype (111113). The alpha2A-adrenergic receptors may mediate the beneficial effects of guanfacine on cognitive function (89). Guanfacine has been used to improve cognitive functioning in many disorders, including schizophrenia, epilepsy, and attention deficit hyperactivity disorder (ADHD) (114118).

In preclinical studies, guanfacine improved attention and working memory in rats (112, 119) and visuomotor (120) and working memory in monkeys (112, 121). In humans, guanfacine improved working memory performance in healthy volunteers (117, 122) and sustained attention in schizophrenics (114) and those with ADHD (123). In preclinical studies, clonidine and lofexidine attenuated the stress-induced reinstatement of cocaine seeking in rats (124, 125), a preclinical model for relapse. Given the more beneficial effects of guanfacine on cognitive functioning, it will be of interest to evaluate its effects for stimulant addiction.

FUTURE DIRECTIONS

The main theme of this review is that medications enhancing inhibitory control and attenuating drug reward may lead to development of effective treatments for stimulant addiction. Table 1 summarizes the relevant studies with these medications. Many questions remain to be addressed about this proposed strategy to use cognitive enhancers targeting Ach and NE for stimulant addiction:

TABLE 1
Proposed Cognitive Enhancers for Stimulant Addiction
  1. Does improving cognition with medications also improve treatment outcome? As summarized above, cognitive deficits in stimulant users, including decision-making, response inhibition, planning, working memory, and attention functions have been well-documented. Studies also indicate that these deficits predict higher drop-out rates and poor treatment response. The medications reviewed improve cognitive function in substance abusers or in other clinical conditions. Nonetheless, this promising chain of evidence fails to make the crucial next step of demonstrating a clinically significant impact on treatment outcome.
  2. What types of treatments will be optimized by use of cognitive enhancing medications in stimulant users? It is possible that cognitive enhancers may be effective for the pharmacotherapy of stimulant addiction in combination with psychosocial treatment. Alternatively, cognitive enhancers could be used to augment response to behavioral treatments for stimulant addiction such as cognitive behavioral therapy (CBT). Although proven to be efficacious, CBT helps only a minority of patients with stimulant addiction (126, 127). Adequate cognitive function is most crucial for behavioral treatments, particularly those like CBT that emphasize cognitive re-training and learning of new behavioral skills, as demonstrated by Aharonovich (35, 36). However, inhibitory function and the ability to maintain awareness of long term goals are key elements of even the most behavioral of treatments such as contingency management. There are examples of augmentation of behavioral treatment with the cognitive enhancer cycloserine for the treatment of phobias and other anxiety disorders (127129) (130). Such augmentation strategies remain to be evaluated for the treatment of stimulant addiction.
    Cognitive-enhancing medications may also optimize the efficacy of other types of medications, especially early in treatment when cognitive function is likely to decline with abstinence from stimulant use. For example, during early phases of cocaine vaccine administration, a promising medication for cocaine addiction (131), antibody titers are insufficient to block large doses of cocaine, and the ability to maintain sobriety during this time may be crucial. Cognitive-enhancing agents may improve outcomes through enhancing patients’ ability to comply with medication regimens. These possibilities need to be evaluated in future controlled studies.
  3. What aspects of improved cognitive function are most strongly related to improved treatment outcome? Although response inhibition is commonly associated with addictive behavior, optimum inhibitory control function depends on other PFC functions, including attention and working memory. The independent contribution of these functions to treatment outcomes needs to be examined in future studies. Further, for each cognitive function of interest, there are many tests to choose from. For example, to evaluate response inhibition in drug users, researchers have used the Stop Signal Test, the Go-No Go test, and the Stroop test (25, 31, 37, 132, 133). This variation across studies makes cross-study comparisons difficult to conduct. Selecting validated cognitive tests with good psychometric properties that are sensitive to pharmacological interventions will be a crucial step. Future clinical studies optimally designed to measure cognitive function as well as drug use behavior are necessary to address these questions.

Acknowledgments

This research was supported by the Veterans Administration Mental Illness Research, Education and Clinical Center (MIRECC) and the National Institute on Drug Abuse grant K02-DA-021304.

References

1. World Drug Report. United Nations Office on Drug Use and Crime 2008
2. Vocci F, Ling W. Medications development: successes and challenges. Pharmacol Ther. 2005;108:94–108. [PubMed]
3. Hill KP, Sofuoglu M. Biological treatments for amfetamine dependence : recent progress. CNS Drugs. 2007;21:851–69. [PubMed]
4. Sofuoglu M, Kosten TR. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs. 2006;11:91–8. [PubMed]
5. Gorelick DA, Gardner EL, Xi ZX. Agents in development for the management of cocaine abuse. Drugs. 2004;64:1547–73. [PubMed]
6. Porrino LJ, Smith HR, Nader MA, Beveridge TJ. The effects of cocaine: a shifting target over the course of addiction. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1593–600. [PMC free article] [PubMed]
7. Everitt BJ, Hutcheson DM, Ersche KD, et al. The orbital prefrontal cortex and drug addiction in laboratory animals and humans. Ann N Y Acad Sci. 2007;1121:576–97. [PubMed]
8. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:1403–13. [PubMed]
9. Vocci FJ. Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda. Exp Clin Psychopharmacol. 2008;16:484–97. [PubMed]
10. Verdejo-Garcia AJ, Lopez-Torrecillas F, Aguilar de Arcos F, Perez-Garcia M. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict Behav. 2005;30:89–101. [PubMed]
11. Robinson JE, Heaton RK, O’Malley SS. Neuropsychological functioning in cocaine abusers with and without alcohol dependence. J Int Neuropsychol Soc. 1999;5:10–9. [PubMed]
12. Jovanovski D, Erb S, Zakzanis KK. Neurocognitive deficits in cocaine users: a quantitative review of the evidence. J Clin Exp Neuropsychol. 2005;27:189–204. [PubMed]
13. Bolla KI, Rothman R, Cadet JL. Dose-related neurobehavioral effects of chronic cocaine use. J Neuropsychiatry Clin Neurosci. 1999;11:361–9. [PubMed]
14. Simon SL, Domier C, Carnell J, et al. Cognitive impairment in individuals currently using methamphetamine. Am J Addict. 2000;9:222–31. [PubMed]
15. Fillmore MT, Rush CR. Impaired inhibitory control of behavior in chronic cocaine users. Drug Alcohol Depend. 2002;66:265–73. [PubMed]
16. Ornstein TJ, Iddon JL, Baldacchino AM, et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000;23:113–26. [PubMed]
17. Simon SL, Domier CP, Sim T, et al. Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis. 2002;21:61–74. [PubMed]
18. Salo R, Nordahl TE, Possin K, et al. Preliminary evidence of reduced cognitive inhibition in methamphetamine-dependent individuals. Psychiatry Res. 2002;111:65–74. [PubMed]
19. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci. 2003;15:317–25. [PubMed]
20. Saxon AJ, Straits-Troster K, Rippeth JD, et al. Longitudinal cognitive changes among methamphetamine dependent patients in early abstinence. Paper presented at the Annual Meeting of College on Problems of Drug Dependence; June 16.2003.
21. Volkow ND, Chang L, Wang GJ, et al. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001;21:9414–8. [PubMed]
22. Volkow ND, Chang L, Wang GJ, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 2001;158:377–82. [PubMed]
23. London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61:73–84. [PubMed]
24. Aron JL, Paulus MP. Location, location: using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use. Addiction. 2007;102(1):33–43. [PubMed]
25. Goldstein RZ, Volkow ND, Wang GJ, Fowler JS, Rajaram S. Addiction changes orbitofrontal gyrus function: involvement in response inhibition. Neuroreport. 2001;12:2595–9. [PMC free article] [PubMed]
26. Sarter M, Bruno JP, Parikh V, et al. Forebrain dopaminergic-cholinergic interactions, attentional effort, psychostimulant addiction and schizophrenia. EXS. 2006;98:65–86. [PubMed]
27. Brennan AR, Arnsten AF. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci. 2008;1129:236–45. [PMC free article] [PubMed]
28. Groman SM, James AS, Jentsch JD. Poor response inhibition: At the nexus between substance abuse and attention deficit/hyperactivity disorder. Neurosci Biobehav Rev 2008 [PMC free article] [PubMed]
29. Swick D, Ashley V, Turken AU. Left inferior frontal gyrus is critical for response Inhibition. BMC Neurosci. 2008;9:102. [PMC free article] [PubMed]
30. De Wit H. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol. 2009;14:22–31. [PMC free article] [PubMed]
31. Hester R, Garavan H. Executive dysfunction in cocaine addiction: evidence for discordant frontal, cingulate, and cerebellar activity. J Neurosci. 2004;24:11017–22. [PubMed]
32. Ersche KD, Clark L, London M, Robbins TW, Sahakian BJ. Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology. 2006;31:1036–47. [PMC free article] [PubMed]
33. Simon SL, Dacey J, Glynn S, Rawson R, Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat. 2004;27:59–66. [PubMed]
34. Woicik PA, Moeller SJ, Alia-Klein N, et al. The neuropsychology of cocaine addiction: recent cocaine use masks impairment. Neuropsychopharmacology. 2009;34:1112–22. [PMC free article] [PubMed]
35. Aharonovich E, Nunes E, Hasin D. Cognitive impairment, retention and abstinence among cocaine abusers in cognitive-behavioral treatment. Drug Alcohol Depend. 2003;71:207–11. [PubMed]
36. Aharonovich E, Hasin DS, Brooks AC, et al. Cognitive deficits predict low treatment retention in cocaine dependent patients. Drug Alcohol Depend. 2006;81:313–22. [PubMed]
37. Streeter CC, Terhune DB, Whitfield TH, et al. Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals. Neuropsychopharmacology. 2008;33:827–36. [PubMed]
38. Moeller FG, Dougherty DM, Barratt ES, et al. The impact of impulsivity on cocaine use and retention in treatment. Journal of Substance Abuse Treatment. 2001;21:193–198. [PubMed]
39. Patkar AA, Murray HW, Mannelli P, et al. Pre-treatment measures of impulsivity, aggression and sensation seeking are associated with treatment outcome for African-American cocaine-dependent patients. J Addict Dis. 2004;23:109–22. [PubMed]
40. Bates ME, Pawlak AP, Tonigan JS, Buckman JF. Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol Addict Behav. 2006;20:241–53. [PMC free article] [PubMed]
41. Donovan DM, Kivlahan DR, Walker RD. Clinical limitations of neuropsychological testing in predicting treatment outcome among alcoholics. Alcohol Clin Exp Res. 1984;8:470–5. [PubMed]
42. O’Leary MR, Donovan DM, Chaney EF, Walker RD. Cognitive impairment and treatment outcome with alcoholics: preliminary findings. J Clin Psychiatry. 1979;40:397–8. [PubMed]
43. Briand LA, Gritton H, Howe WM, Young DA, Sarter M. Modulators in concert for cognition: modulator interactions in the prefrontal cortex. Prog Neurobiol. 2007;83:69–91. [PMC free article] [PubMed]
44. Shearer J, Wodak A, Mattick RP, et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. Addiction. 2001;96:1289–96. [PubMed]
45. Grabowski J, Roache JD, Schmitz JM, et al. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol. 1997;17:485–8. [PubMed]
46. Grabowski J, Shearer J, Merrill J, Negus SS. Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav. 2004;29:1439–64. [PubMed]
47. Kollins SH. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD) Am J Addict. 2007;16(1):35–42. quiz 43–4. [PubMed]
48. Shearer J, Darke S, Rodgers C, et al. A double-blind, placebo-controlled trial of modafinil (200 mg/day) for methamphetamine dependence. Addiction. 2009;104:224–33. [PubMed]
49. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA. 2009;301:1148–54. [PMC free article] [PubMed]
50. Sofuoglu M, Mooney M. Cholinergic Functioning in Stimulant Addiction:Implications for Medications Development. CNS Drugs. 2009 in press. [PMC free article] [PubMed]
51. Sofuoglu M, Sewell RA. Norepinephrine and stimulant addiction. Addict Biol. 2009;14:119–29. [PMC free article] [PubMed]
52. Lucas-Meunier E, Fossier P, Baux G, Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch. 2003;446:17–29. [PubMed]
53. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273–80. [PubMed]
54. Smythies J. Section I. The cholinergic system. Int Rev Neurobiol. 2005;64:1–122. [PubMed]
55. Mesulam MM. The cholinergic innervation of the human cerebral cortex. Prog Brain Res. 2004;145:67–78. [PubMed]
56. Cragg SJ. Meaningful silences: how dopamine listens to the ACh pause. Trends Neurosci. 2006;29:125–31. [PubMed]
57. Berlanga ML, Olsen CM, Chen V, et al. Cholinergic interneurons of the nucleus accumbens and dorsal striatum are activated by the self-administration of cocaine. Neuroscience. 2003;120:1149–56. [PubMed]
58. Miller HL, Ekstrom RD, Mason GA, Lydiard RB, Golden RN. Noradrenergic function and clinical outcome in antidepressant pharmacotherapy. Neuropsychopharmacology. 2001;24:617–23. [PubMed]
59. Kozak R, Martinez V, Young D, et al. Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. Neuropsychopharmacology. 2007;32:2074–86. [PubMed]
60. Sarter M, Martinez V, Kozak R. A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia. Psychopharmacology (Berl) 2008;202:237–58. [PMC free article] [PubMed]
61. Hikida T, Kaneko S, Isobe T, et al. Increased sensitivity to cocaine by cholinergic cell ablation in nucleus accumbens. Proc Natl Acad Sci U S A. 2001;98:13351–4. [PubMed]
62. de la Garza R, Johanson CE. Effects of haloperidol and physostigmine on self-administration of local anesthetics. Pharmacol Biochem Behav. 1982;17:1295–9. [PubMed]
63. Takamatsu Y, Yamanishi Y, Hagino Y, Yamamoto H, Ikeda K. Differential effects of donepezil on methamphetamine and cocaine dependencies. Ann N Y Acad Sci. 2006;1074:418–26. [PubMed]
64. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006:CD005593. [PubMed]
65. Farlow M. A clinical overview of cholinesterase inhibitors in Alzheimer’s disease. Int Psychogeriatr. 2002;14(1):93–126. [PubMed]
66. Giacobini E. Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res. 2004;50:433–40. [PubMed]
67. Camicioli R, Gauthier S. Clinical trials in Parkinson’s disease dementia and dementia with Lewy bodies. Can J Neurol Sci. 2007;34(1):S109–17. [PubMed]
68. Ochoa EL, Clark E. Galantamine may improve attention and speech in schizophrenia. Hum Psychopharmacol. 2006;21:127–8. [PubMed]
69. Khateb A, Ammann J, Annoni JM, Diserens K. Cognition-enhancing effects of donepezil in traumatic brain injury. Eur Neurol. 2005;54:39–45. [PubMed]
70. Schilstrom B, Ivanov VB, Wiker C, Svensson TH. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology. 2007;32:43–53. [PubMed]
71. Marco-Contelles J, do Carmo Carreiras M, Rodriguez C, Villarroya M, Garcia AG. Synthesis and pharmacology of galantamine. Chem Rev. 2006;106:116–33. [PubMed]
72. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. Antagonistic effects of physostigmine and methylphenidate in man. Am J Psychiatry. 1973;130:1370–6. [PubMed]
73. De La Garza R, 2nd, Mahoney JJ, 3rd, Culbertson C, Shoptaw S, Newton TF. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav. 2008;89:200–8. [PMC free article] [PubMed]
74. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction. 2005;100(1):68–77. [PubMed]
75. Sofuoglu M, Poling J, Sewell A, et al. Galantamine effects on cogntive function in abstient cocaine users. 2009 in submission.
76. Dunbar G, Boeijinga PH, Demazieres A, et al. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berl) 2007;191:919–29. [PubMed]
77. Gulick D, Gould TJ. Varenicline ameliorates ethanol-induced deficits in learning in C57BL/6 mice. Neurobiol Learn Mem. 2008;90:230–6. [PMC free article] [PubMed]
78. Raybuck JD, Portugal GS, Lerman C, Gould TJ. Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice. Behav Neurosci. 2008;122:1166–71. [PMC free article] [PubMed]
79. Patterson F, Jepson C, Strasser AA, et al. Varenicline improves mood and cognition during smoking abstinence. Biol Psychiatry. 2009;65:144–9. [PMC free article] [PubMed]
80. Hiranita T, Nawata Y, Sakimura K, Anggadiredja K, Yamamoto T. Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci U S A. 2006;103:8523–7. [PubMed]
81. Kouri EM, Stull M, Lukas SE. Nicotine alters some of cocaine’s subjective effects in the absence of physiological or pharmacokinetic changes. Pharmacol Biochem Behav. 2001;69:209–17. [PubMed]
82. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474–7. [PubMed]
83. Huether G. The central adaptation syndrome: psychosocial stress as a trigger for adaptive modifications of brain structure and brain function. Prog Neurobiol. 1996;48:569–612. [PubMed]
84. Sved AF, Cano G, Card JP. Neuroanatomical specificity of the circuits controlling sympathetic outflow to different targets. Clin Exp Pharmacol Physiol. 2001;28:115–9. [PubMed]
85. Smythies J. Section III. The norepinephrine system. Int Rev Neurobiol. 2005;64:173–211. [PubMed]
86. Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev. 1994;46:121–36. [PubMed]
87. Chamberlain SR, Muller U, Blackwell AD, et al. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science. 2006;311:861–3. [PMC free article] [PubMed]
88. Dalley JW, Mar AC, Economidou D, Robbins TW. Neurobehavioral mechanisms of impulsivity: fronto-striatal systems and functional neurochemistry. Pharmacol Biochem Behav. 2008;90:250–60. [PubMed]
89. Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007;113:523–36. [PMC free article] [PubMed]
90. Grenhoff J, Nisell M, Ferre S, Aston-Jones G, Svensson TH. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect. 1993;93:11–25. [PubMed]
91. Lategan AJ, Marien MR, Colpaert FC. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 1990;523:134–8. [PubMed]
92. Paladini CA, Williams JT. Noradrenergic inhibition of midbrain dopamine neurons. J Neurosci. 2004;24:4568–75. [PubMed]
93. Sora I, Igari M, Yamamoto H, Ikeda K. Monoamine transporter as a target molecule for psychostimulants. Nippon Yakurigaku Zasshi. 2007;130:450–4. [PubMed]
94. Szerman N, Peris L, Mesias B, et al. Reboxetine for the treatment of patients with Cocaine Dependence Disorder. Hum Psychopharmacol. 2005;20:189–92. [PubMed]
95. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27:699–711. [PubMed]
96. Swanson CJ, Perry KW, Koch-Krueger S, et al. Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology. 2006;50:755–60. [PubMed]
97. Carboni E, Tanda GL, Frau R, Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem. 1990;55:1067–70. [PubMed]
98. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68:2032–7. [PubMed]
99. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002;67:149–56. [PubMed]
100. Wee S, Woolverton WL. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug Alcohol Depend. 2004;75:271–6. [PubMed]
101. Robinson ES, Eagle DM, Mar AC, et al. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology. 2008;33:1028–37. [PubMed]
102. Jentsch JD, Aarde SM, Seu E. Effects of atomoxetine and methylphenidate on performance of a lateralized reaction time task in rats. Psychopharmacology (Berl) 2009;202:497–504. [PubMed]
103. Seu E, Lang A, Rivera RJ, Jentsch JD. Inhibition of the norepinephrine transporter improves behavioral flexibility in rats and monkeys. Psychopharmacology (Berl) 2009;202:505–19. [PMC free article] [PubMed]
104. Newman LA, Darling J, McGaughy J. Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl) 2008;200:39–50. [PubMed]
105. Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2007;62:977–84. [PubMed]
106. Faraone SV, Biederman J, Spencer T, et al. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2005;15:664–70. [PubMed]
107. Li CS, Milivojevic V, Kemp K, Hong K, Sinha R. Performance monitoring and stop signal inhibition in abstinent patients with cocaine dependence. Drug Alcohol Depend. 2006;85:205–12. [PubMed]
108. Monterosso JR, Aron AR, Cordova X, Xu J, London ED. Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend. 2005;79:273–7. [PubMed]
109. Sofuoglu M, Hill K, Kosten T, Poling J. Atomoxetine Attenuates Dextroamphetamine Effects in Humans. 2009 in submission. [PMC free article] [PubMed]
110. Griffiths RR, Bigelow GE, Ator NA. Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend. 2003;70:S41–54. [PubMed]
111. Nami R, Bianchini C, Fiorella G, Chierichetti SM, Gennari C. Comparison of effects of guanfacine and clonidine on blood pressure, heart rate, urinary catecholamines, and cyclic nucleotides during and after administration to patients with mild to moderate hypertension. J Cardiovasc Pharmacol. 1983;5:546–51. [PubMed]
112. Ramos BP, Stark D, Verduzco L, van Dyck CH, Arnsten AF. Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals. Learn Mem. 2006;13:770–6. [PubMed]
113. Spiegel R, DeVos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol. 1980;10(1):165S–168S. [PMC free article] [PubMed]
114. Friedman JI, Adler DN, Temporini HD, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropsychopharmacology. 2001;25:402–9. [PubMed]
115. McClure MM, Barch DM, Romero MJ, et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry. 2007;61:1157–60. [PubMed]
116. Posey DJ, McDougle CJ. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev. 2007;13:465–74. [PubMed]
117. Swartz BE, McDonald CR, Patel A, Torgersen D. The effects of guanfacine on working memory performance in patients with localization-related epilepsy and healthy controls. Clin Neuropharmacol. 2008;31:251–60. [PubMed]
118. Arnsten AF. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology. 2006;31:2376–83. [PubMed]
119. Sagvolden T. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD) Behav Brain Funct. 2006;2:41. [PMC free article] [PubMed]
120. Wang M, Tang ZX, Li BM. Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res. 2004;1024:176–82. [PubMed]
121. Rama P, Linnankoski I, Tanila H, Pertovaara A, Carlson S. Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacol Biochem Behav. 1996;55:415–22. [PubMed]
122. Jakala P, Riekkinen M, Sirvio J, et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 1999;20:460–70. [PubMed]
123. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158:1067–74. [PubMed]
124. Erb S, Hitchcott PK, Rajabi H, et al. Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology. 2000;23:138–50. [PubMed]
125. Highfield D, Yap J, Grimm JW, Shalev U, Shaham Y. Repeated lofexidine treatment attenuates stress-induced, but not drug cues-induced reinstatement of a heroin-cocaine mixture (speedball) seeking in rats. Neuropsychopharmacology. 2001;25:320–31. [PubMed]
126. Carroll KM, Ball SA, Martino S, et al. Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT. Am J Psychiatry. 2008;165:881–8. [PMC free article] [PubMed]
127. Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008;27:309–17. [PubMed]
128. Ressler KJ, Rothbaum BO, Tannenbaum L, et al. Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136–44. [PubMed]
129. Wilhelm S, Buhlmann U, Tolin DF, et al. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry. 2008;165:335–41. quiz 409. [PubMed]
130. McNally RJ. Mechanisms of exposure therapy: how neuroscience can improve psychological treatments for anxiety disorders. Clin Psychol Rev. 2007;27:750–9. [PubMed]
131. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry. 2005;58:158–64. [PubMed]
132. Li CS, Huang C, Yan P, et al. Neural correlates of impulse control during stop signal inhibition in cocaine-dependent men. Neuropsychopharmacology. 2008;33:1798–806. [PMC free article] [PubMed]
133. Lane SD, Moeller FG, Steinberg JL, Buzby M, Kosten TR. Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty. Am J Drug Alcohol Abuse. 2007;33:717–26. [PubMed]
134. Stoops WW, Blackburn JW, Hudson DA, Hays LR, Rush CR. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance. Drug Alcohol Depend. 2008;92:282–5. [PMC free article] [PubMed]